Section 5: Patient Safety and Quality Assurance 2021 Help me understand this report
5PSQ-164 Real safety of daratumumab in myeloma multiple
Abstract: reductions were not associated with an increased risk of progression. Bone metastasis is very common in metastatic or locally advanced breast cancer. Since the authorisation for firstline use (PALOMA-2) it has become a standard of treatment for metastatic or locally advanced breast cancer.
This publication either has no citations yet, or we are still processing them
Set email alert for when this publication receives citations?
See others like this or search for similar articles
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
